What we stand for
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Our expertise & offering
Quantoom Biosciences accelerates the transition towards RNA-based therapeutics. Through its end-to-end N-Force toolbox, it enables its clients to turn any antigen into a high-performing sa/mRNA-LNP drug candidate. It relies on three complementary pillars — Ncode, Ntensify®, and Ncapsulate® QCX — to design, produce, and formulate RNA ready for preclinical or clinical studies. Our Ncode platform maximizes the potential of any antigen by optimizing the nucleic acid sequence, the Ntensify product line provides a scalable and construct-agnostic RNA production and purification platform, and the Ncapsulate lipid library enables RNA formulation for de-risked therapeutics. Taken together, our N-Force toolbox offers the best end-to-end solution for any organization looking to transition to RNA-based therapeutics.
Expertise in Sequence design & optimization for sa/mRNA
We transform any antigen of interest into a fully optimized sa/mRNA construct, using a proven combination of design tools and scientific know-how. We guide our partners from the amino acid sequence to an optimized DNA template, ensuring that each construct is optimized for DNA manufacturing, RNA stability, and protein expression. Whether it is for infectious diseases through mosaic antigen designs or for oncology applications with mini-gene constructs, we have built extensive experience through our numerous partnerships with top-tier institutions such as the University of Arizona, Memorial Sloan Kettering Cancer Center, and Vaxthera. Our track record of successful designs has given us the capabilities to help accelerate and de-risk RNA development from the very first step.
Expertise in integrated and scalable RNA manufacturing
We have developed Ntensify as a fully integrated, scalable solution that redefines how RNA is produced. By combining process intensification, advanced design principles, and years of optimization, we enable high-yield RNA manufacturing with a drastically reduced footprint, fewer manual steps, and improved product consistency. Ntensify is designed to be construct-agnostic, easy to implement, and seamless to scale—from early R&D quantities to commercial-scale production. This approach reduces costs, increases reliability, and supports the broader availability of life-saving biologics.
The Ntensify process combines IVT and purification to streamline operations. The IVT step uses co-transcriptional capping with TriLink’s CleanCAP and has been optimized to produce minimal impurities, facilitating downstream purification. This optimization enables a transition to a single-step purification method based on magnetic silica beads, replacing the multiple conventional chromatographies and TFF steps typically required for bulk purification.
We provide a complete range of Ntensify platforms designed to support every stage of RNA development, from early construct assessment at R&D scale to clinical and commercial production. Our product line includes the Ntensify® mano, micro, mini, and midi systems, offering flexible capacities, scalable outputs, and increasing levels of automation—allowing partners to efficiently produce mRNA or saRNA from microgram to gram scale.
Expertise in high-performance RNA formulation
We developed delivery chemistries — Ncapsulate® QCX — designed to enhance mRNA and saRNA delivery across a wide range of in-vivo applications, drawing on deep formulation know-how and years of in-species validation to create lipid-like systems that consistently increase protein expression where it matters.
Keeping therapeutic applications in mind, we tailored our kits for in-vivo use with customized chemistries for intravenous and intramuscular administration, while also offering solutions for in-vitro R&D for both mRNA and saRNA.
We offer Ncapsulate QCX as a flexible delivery solution available in multiple formats to support a wide range of RNA programs.
- Ncapsulate® QCX core – our raw material enables clients accustomed to formulation to rapidly adopt our core lipid and start delivering RNA where it matters.
- Ncapsulate® QCX combo – our ready-to-formulate kits for rapid evaluation or fully customized LNP development for specific delivery needs.
- Ncapsulate® QCX carrier – our ready-to-use pre-encapsulated particles that can be formulated using simple mixers, without ethanol and need for downstream TFF.
- Ncapsulate® QCX custom – seeking a different solution compared to our off-the-shelf offering, we are geared to tailor our lipid, lipid mix and manufacturing process.
Our offering is designed to adapt to your preferred workflow—off-the-shelf, custom-configured, or raw material supply—ensuring reliable and scalable RNA formulation from early research through advanced development, while maintaining a solid IP position and a clear path to commercialization.
Our partners
Our global collaborations
Since its commercial launch in 2023, Quantoom Biosciences has installed 25 Ntensify® systems worldwide and has five ongoing R&D collaborations.
Diversity & values
At Quantoom Biosciences, we stand for inclusivity, diversity, and respect for individual differences. We strive to practice equality across the board, from our hiring methods to how we pay employees. Our team represents many diverse backgrounds and perspectives.
Accountability
We own and assume accountability for results, we establish high-performance standards
Continuous improvement
We challenge the status quo, embrace innovation, add value, and deliver operational excellence
Teach/lead
We value and solicit new ideas, develop and refine competencies by sharing knowledge and experience
Integrity
We maintain high ethical standards; respect, include and recognize differences
Team
Everyone acts as a team builder, we remove the barriers that block the team’s success
Our team
Management Team
Click on each picture to see the bio of each member
Jose Castillo, PhD.
Chief Executive Officer
Jose Castillo, PhD.
Chief Executive Officer
José Castillo is the Chief Executive Officer of Quantoom Biosciences, a biotech company founded in 2021 that operates as a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Prior to Quantoom Biosciences, José co-founded Univercells in 2013, where he played a key role in the development of innovative, highly efficient biopharmaceutical manufacturing technologies aimed at improving global access to biologics. During this period, he contributed to the vision of disruptive, end-to-end manufacturing solutions for the biopharmaceutical industry.
Building on more than two decades of experience, José is a recognized technology leader in bioprocessing and industrial biotechnology. His career includes the founding of Artelis, where he designed and developed breakthrough fixed-bed bioreactor technologies. The resulting iCELLis® system has since become a reference standard in the vaccines and gene therapy industry and was later industrialized at ATMI LifeSciences and Pall Life Sciences, where José held senior leadership roles in Cell Culture Technologies.
Earlier in his career, José served as Manager of Viral Vaccines Industrialization at GSK Vaccines, contributing to large-scale vaccine manufacturing operations.
José holds a PhD in Applied Sciences (Chemical Engineering) from the Université Libre de Bruxelles and an entrepreneurship degree from Solvay Business School.
Rachana Talwar
Chief of staff & Chief Operating Officer
Rachana Talwar
Chief of staff & Chief Operating Officer
With over 15 years of international experience across India, France, and Belgium, she brings extensive operational and strategic expertise to Quantoom. She holds a Master’s degree in Management and has a proven track record of managing complex, cross-functional projects across varied sectors. In her role as COO, she is driving the supply chain, manufacturing, project management, quality, maintenance, and laboratory support functions.
She has been with Quantoom Biosciences since its inception and has played a pivotal role in the setup, development, and industrialization of the organization. Prior to Quantoom, her career spanned reputed global organizations including Springer India and GSK, providing her with broad exposure across diverse industries and operating environments.
Currently serving as Chief of Staff and COO at Quantoom Biosciences in Belgium, she is a dynamic, multilingual leader whose international experience and cross-disciplinary mindset continue to drive operational excellence and innovation.
Ashiqul Haque, PhD.
Chief Scientific Officer
Ashiqul Haque, PhD.
Chief scientific officer
Ashiqul Haque is an accomplished biochemist with over a decade of experience in mRNA-based drug development. He earned his PhD from the University of Tübingen in collaboration with CureVac and TriLink, focusing on mRNA-based gene supplementation and correction therapy for Cystic Fibrosis. His research has led to multiple first-author publications in high-impact journals, including Molecular Therapy and Nature Communications, and he is the inventor on several patents covering chemical modifications of mRNA and lipid/LNP library creation for RNA-based therapeutics. Currently serving as CSO at Quantoom, Ashiqul plays a central role in guiding the company’s mRNA and saRNA programs for both vaccination and therapeutic applications. He oversees the full technical and scientific pipeline—from molecular design (antigen, mRNA, and plasmid engineering) to drug substance development (self-amplifying RNA formulated in lipid nanoparticles)—ensuring every stage meets rigorous innovation and quality standards. Ashiqul’s blend of deep scientific expertise, patent-backed innovation, and strategic project leadership continues to drive forward the next generation of RNA-based medicines.
Coralie Pirlot
Chief Financial Officer
Coralie Pirlot
Chief Financial Officer
With over a decade of international experience across multiple industries and roles, Coralie is a seasoned finance professional skilled at steering organizations through complex business environments. She currently serves as the Chief Financial Officer at Quantoom Biosciences, where she oversees all financial operations and drives the company’s financial strategy, planning, and performance.
Prior to joining Quantoom Biosciences, Coralie was Group FP&A Manager at Atalian, a major player in the facility management sector. Leading a team of FP&A analysts, she played a key role in corporate performance analysis, budgeting, forecasting, and procurement controlling, ensuring strong alignment between financial insights and organizational objectives.
Coralie also gained significant experience in the pharmaceutical industry as Senior Project Lead at Galapagos, where she developed commercial controlling processes and provided financial support for both operational and strategic decision-making. Her work strengthened financial excellence, business partnering, and process optimization in a competitive biotech landscape.
Earlier in her career, Coralie held leadership roles in the legal sector at Morgan Lewis & Bockius LLP, across both the USA and the UK. As Manager of Business Operations for EMEA and Asia Pacific, she oversaw financial planning, reporting, pricing strategy, and client rate management, contributing to improved operational efficiency and enhanced client satisfaction.
Coralie began her career in banking at ING Belgium, working in corporate sales and associate relationship management. There, she advised large corporations on financial risk hedging and executed financial market products, building a strong foundation in client relationship management, financial analysis, and regulatory compliance.
Throughout her career, Coralie has demonstrated a consistent commitment to excellence, adaptability, and impact. With a proven track record across finance, operations, and strategic leadership, she continues to bring strong value to Quantoom Biosciences as it accelerates innovation in RNA-based technologies.
Hala Audi
Global Director Alliance & Partnership
Hala Audi
Global Director Alliance & Partnership
Hala‘s career spans 20 years in government, global health and life sciences, including CEO roles and UK Treasury Director. She has international experience shaping major portfolios, building partnerships across sectors, and enabling scientific and policy innovation to translate into measurable impact. Since 2022 her work has focused on supporting clients to build GLP and GMP biomanufacturing sites to meet the rising demand for RNA based vaccines and therapeutics.
Noémie Jacquart
Head of Marketing & Sales Operations
Noémie Jacquart
Head of Marketing & Sales Operations
Noémie Jacquart brings over 6+ years of experience in strategy, market growth and expansion, grounded in a deep understanding of customer needs, market dynamics, and product value creation. She holds a master’s degree in business engineering from Solvay Brussels School of Economics and Management. Prior to her current role, she worked as a strategy consultant at Monitor Deloitte and as Global Practice Manager at Arthur D. Little, supporting global leadership teams on practice strategy, performance management, and go-to-market initiatives.
In her current role, she drives Marketing activities spanning strategic marketing, go-to-market approaches, product portfolio management, as well as Sales Operations activities enabling to drive key business intelligence. She is also actively involved in the Scientific & Business Strategy Committee, supporting the Board in Quantoom’s strategic positioning and long-term vision.
Youlia Serikova, PhD.
Head of N-Force Process
Youlia Serikova, PhD.
Head of Process Development
Youlia Serikova holds a PhD in Cell Biology and Biochemistry and has more than 10 years of industrial experience in biotechnology and bioprocessing related to cell biology, viral vector production, and molecular biology.
Her work bridges scientific innovation and industrial implementation in a wide range of disciplines.
Throughout her career, she has led development of technical assets within cell therapy and biotechnology companies.
She began her career through industrial PhD collaborations in engineering of biomimetic surfaces for stem cell bioprocessing. She later contributed to upstream process development for biotherapeutics and viral vaccines production.
She has authored publications on peptide-based matrices and animal-free cell culture technologies.
At Quantoom Biosciences, she progressed through roles in RNA research and process development. As Head of Process Development and Industrialization, she currently leads the development of processes and capabilities in design and production of next-generation RNA-based medicines, aligning scientific research with practical bioprocessing and industrial implementation. She also co-leads global projects focused on RNA-based vaccine development.
Laurent Heusgens
Head of Engineering and Services
Laurent Heusgens
Head of Engineering and Services
Laurent Heusgens is an experienced Engineer and Manager with 20 years of expertise in the pharmaceutical and biotechnology industries, working in highly regulated cGMP environments within both CDMOs and large international companies.
Throughout his career, Laurent has held key roles including Subject Matters Expert and Manager.
He has been deeply involved in the design, installation, commissioning, validation, and start-up of drug substance, viral vector, and RNA manufacturing facilities, from laboratory to industrial scale.
More recently, at Quantoom, Laurent contributed to the deployment of innovative RNA solutions. He currently serves as Head of Head of N-Force Products, where he led the Engineering and Services department, defining Design, Industrialization, Production, Installation, Verification and Maintenance of RNA production equipment.
Maria Davila-Saignol
Global Director Sales & Business Dev.
Maria Davila-Saignol
Global Director Sales & Business Dev.
Available soon.
Key experts
Our team brings deep expertise across a broad range of capabilities
Anne de Lamotte, PhD.
Tech Lead Engineer
Laura Deruyver, PhD.
Scientist
Maxime Bollengier
RNA Design Lead
Nathalie Dumoulin
QA Manager
Sales Team
Our sales team operates globally, ensuring seamless support in every region
Maria Davila-Saignol
Global Director Sales & Business Dev.
Didier Argentin
Director Sales Europe
James Timmins
Senior Business Developer, North America
Wen Hong Toh
Senior Business Developer, APAC
Our history
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Built around our N-Force toolbox — Ncode for sequence design, Ntensify® for scalable RNA production, and Ncapsulate® for RNA-LNP formulation — our platform turns any antigen into a high-quality (sa)mRNA-LNP drug product. Beyond technology, Quantoom Biosciences supports partners with extensive enabling services, from strategic R&D collaborations to sequence design and optimization.
University of Western Australia selects Ntensify® mini for advanced RNA research
The University of Western Australia’s RNA Innovation Foundry selects Quantoom Biosciences’ Ntensify® mini platform to support cutting-edge RNA research and technology development. This adoption highlights Quantoom’s growing footprint in academic research and innovation ecosystems, and its role in enabling the next generation of RNA-based therapies.
Restructuring and creation of Phoenix Biosciences as a standalone company
Quantoom Biosciences enters a new phase under the legal entity Phoenix Biosciences SA, through which all activities and technologies now continue. This restructuring provides a clear and solid foundation for the future, strengthening our position as a full-stack RNA solutions provider.
Research collaboration with Leading Global Cancer Center
Quantoom Biosciences signs a research license and supply agreement with Memorial Sloan Kettering Cancer Center to support the development of personalized mRNA-based cancer therapeutics. This collaboration confirms Quantoom’s expansion into high-value clinical research and oncology applications, reinforcing the versatility of its mRNA formulation and manufacturing technologies.
Launch of the Ntensify micro
Quantoom Biosciences launches the Ntensify® micro, expanding the R&D segment of its Ntensify® product line. The Ntensify® micro is the smallest and most compact system designed for the Ntensify® process. This benchtop unit enables the production and purification of 500 µg to 100 mg of high-quality mRNA in just 4 to 6 hours.
Belgium and Brazil unite to advance RNA-based therapies
Quantoom Biosciences signs a Memorandum of Understanding with Bio-Manguinhos/Fiocruz, strengthening international cooperation to accelerate the development and local production of RNA-based therapeutics. This milestone reflects Quantoom’s growing role as a global technology enabler, supporting sovereign manufacturing strategies beyond vaccines.
Strategic collaboration with Serum Institute of India
Quantoom Biosciences enters into a strategic collaboration with the world’s largest vaccine manufacturer to expand the accessibility of RNA-based personalized oncology and immunotherapies. This partnership marks a major step beyond vaccines, demonstrating Quantoom’s ability to support point-of-care, small-scale mRNA manufacturing for advanced therapeutic applications worldwide.
Launch of the Ntensify mano
Quantoom Biosciences announces the extension of the Ntensify product line with the launch of Ntensify mano, an mRNA kit containing mixes of reagents for mRNA production and purification for research use.
Installation of the 1st Ntensify midi
Quantoom Biosciences announces the installation of its first Ntensify midi system for mRNA vaccine production in the GMP facility of Afrigen Biologics in Cape Town, South Africa. (under 19 months of dev…)
Agreement for the first African-owned Covid-19 vaccine
The collaboration with Afrigen Biologics (hosting the World Health Organization’s Global mRNA Vaccine Technology Transfer Hub) will focus on the development of a novel mRNA vaccine that will drastically accelerate access to vaccination by using Quantoom’s mRNA production technology.
Collaboration with eTheRNA
Quantoom entered into a strategic collaboration to build an advanced, small footprint technology platform for the affordable production of RNA-based therapies. This platform was designed to be used either within existing facilities or rapidly deployed to areas of urgent need.
Official launch of Quantoom Biosciences
The COVID-19 pandemic underlined the desperate need for technological innovation in manufacturing to provide a simple, scalable way to make RNA. By lowering the barriers to RNA production, we allow our partners that have previously not considered exploring RNA-based vaccines and therapeutics, to gain access to RNA production capabilities and enter the market.